The use of breast imaging for predicting response to neoadjuvant lapatinib, trastuzumab and their combination in HER2-positive breast cancer: Results from Neo-ALTTO

被引：12

作者：

Di Cosimo, S. ^{[1
]}

Campbell, C. ^{[2
]}

Azim, H. A., Jr. ^{[3
]}

Galli, G. ^{[1
]}

Bregni, G. ^{[4
]}

Curigliano, G. ^{[5
]}

Criscitiello, C. ^{[5
]}

Izquierdo, M. ^{[6
]}

de la Pena, L. ^{[7
]}

Fumagalli, D. ^{[8
]}

Fein, L. ^{[9
]}

Vinholes, J. ^{[10
]}

Ng, W. M. J. ^{[11
]}

Colleoni, M. ^{[12
]}

Ferro, A. ^{[13
]}

Naume, B. J. ^{[14
]}

Patel, A. ^{[15
]}

Huober, J. ^{[16
]}

Piccart-Gebhart, M. J. ^{[3
]}

Baselga, J. ^{[17
]}

de Azambuja, E. ^{[3
]}

机构：

[1] Ist Nazl Tumori Milano, Fdn IRCCS, Milan, Italy

[2] Frontier Sci Scotland Ltd, Kincraig, Scotland

[3] ULB, Inst Jules Bordet, Brussels, Belgium

[4] IRCCS AOU S Martino IST, Genoa, Italy

[5] European Inst Oncol, Milan, Italy

[6] Novartis Pharma AG, Basel, Switzerland

[7] SOLTI Breast Canc Res Grp, Barcelona, Spain

[8] Breast Int Grp, Brussels, Belgium

[9] Inst Oncol Rosario, Rosario, Santa Fe, Argentina

[10] Clin Oncol, Porto Alegre, RS, Brazil

[11] Queen Elizabeth Hosp, Hong Kong, Hong Kong, Peoples R China

[12] Ist Europeo Oncol, Milan, Italy

[13] Osped Trento, Trento, Italy

[14] Oslo Univ Hosp, Oslo, Norway

[15] Princess Alexandra Hosp NHS Trust, Harlow, Essex, England

[16] Ulm Univ Hosp, Ulm, Germany

[17] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

来源：

EUROPEAN JOURNAL OF CANCER | 2018年 / 89卷

关键词：

HER2 positive breast cancer; Targeted therapy; Neoadjuvant; Mammography; Breast ultrasound; PATHOLOGICAL COMPLETE RESPONSE; OPEN-LABEL; PHASE-3; TRIAL; TUMOR SIZE; CHEMOTHERAPY; ACCURACY; SURVIVAL; MULTICENTER; MAMMOGRAPHY; SAFETY;

D O I：

10.1016/j.ejca.2017.10.036

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Aim: To determine the value of mammography and breast ultrasound (US) in predicting outcomes in HER2 positive breast cancer patients (pts) within Neo-ALTTO trial. Patients and methods: Mammography and US were required at baseline, week 6 and surgery. Two independent blinded investigators reviewed the measurements and assigned the corresponding response category. Pts showing complete or partial response according to RECIST (v1.1) were classified as responders. The association between imaging response at week 6 or prior to surgery was evaluated with respect to pathological complete response (pCR) and event-free Survival (EFS). Results: Of the 455 pts enrolled in the trial, 267 (61%) and 340 (77%) had evaluable mammography and US at week 6; 248 (56%) and 309 (70%) pts had evaluable mammography and US prior to surgery. At week 6, 32% and 43% of pts were classified as responders by mammography and US, respectively. pCR rates were twice as high for responders than non-responders (week 6: 46% versus 23% by US, p < 0.0001; 41% versus 24% by mammography, p = 0.007). Positive and negative predictive values of mammography and US prior to surgery were 37% and 35%, and 82% and 70%, respectively. No significant correlation was found between response by mammography and/or US at week 6/surgery and EFS. Conclusions: Mammography and US were underused in Neo-ALTTO although US had the potential to assess early response whereas mammography to detect residual disease prior to surgery. Our data still emphasise the need for further imaging studies on pts treated with neoadjuvant HER2-targeted therapy. (C) 2017 Elsevier Ltd. All rights reserved.

引用

页码：42 / 48

页数：7

共 27 条

[21]

Schulz-Wendtland Rudiger, 2012, Eur J Radiol, V81 Suppl 1, pS147, DOI 10.1016/S0720-048X(12)70061-X

[22]

Semiglazov Vladimir, 2015, Journal of the National Cancer Institute Monographs, P21, DOI 10.1093/jncimonographs/lgv021

[23] HUMAN-BREAST CANCER - CORRELATION OF RELAPSE AND SURVIVAL WITH AMPLIFICATION OF THE HER-2 NEU ONCOGENE [J].

SLAMON, DJ ;

CLARK, GM ;

WONG, SG ;

LEVIN, WJ ;

ULLRICH, A ;

MCGUIRE, WL .

SCIENCE, 1987, 235 (4785) :177-182

[24] A phase Ill trial of adjuvant capecitabine in breast cancer patients with HER2-negative pathologic residual invasive disease after neoadjuvant chemotherapy (CREATE-X, JBCRG-04) [J].

Toi, M. ;

Lee, S-J ;

Lee, E. S. ;

Ohtani, S. ;

Im, Y-H ;

Im, S-A ;

Park, B-W ;

Kim, S-B ;

Yanagita, Y. ;

Takao, S. ;

Ohno, S. ;

Aogi, K. ;

Iwata, H. ;

Kim, A. ;

Sasano, H. ;

Yokota, I. ;

Ohashi, Y. ;

Masuda, N. .

CANCER RESEARCH, 2016, 76

[25] Response-Guided Neoadjuvant Chemotherapy for Breast Cancer [J].

von Minckwitz, Gunter ;

Blohmer, Jens Uwe ;

Costa, Serban Dan ;

Denkert, Carsten ;

Eidtmann, Holger ;

Eiermann, Wolfgang ;

Gerber, Bernd ;

Hanusch, Claus ;

Hilfrich, Joern ;

Huober, Jens ;

Jackisch, Christian ;

Kaufmann, Manfred ;

Kuemmel, Sherko ;

Paepke, Stefan ;

Schneeweiss, Andreas ;

Untch, Michael ;

Zahm, Dirk Michael ;

Mehta, Keyur ;

Loibl, Sibylle .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (29) :3623-+

[26] Is 18F-FDG PET accurate to predict neoadjuvant therapy response in breast cancer? A meta-analysis [J].

Wang, Yuting ;

Zhang, Chengpeng ;

Liu, Jianjun ;

Huang, Gang .

BREAST CANCER RESEARCH AND TREATMENT, 2012, 131 (02) :357-369

[27] Prospective comparison of mammography, sonography, and MRI in patients undergoing neoadjuvant chemotherapy for palpable breast cancer [J].

Yeh, E ;

Slanetz, P ;

Kopans, DB ;

Rafferty, E ;

Georgian-Smith, D ;

Moy, L ;

Halpern, E ;

Moore, R ;

Kuter, I ;

Taghian, A .

AMERICAN JOURNAL OF ROENTGENOLOGY, 2005, 184 (03) :868-877

← 1 2 3 →